CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

213931Orig1s000

OTHER REVIEW(S)

MEMORANDUM

REVIEW OF REVISED LABEL AND LABELING

Division of Medication Error Prevention and Analysis 2 (DMEPA 2)

Office of Medication Error Prevention and Risk Management (OMEPRM)

Office of Surveillance and Epidemiology (OSE)

Center for Drug Evaluation and Research (CDER)

Date of This Memorandum:	10/17/2023
Requesting Office or Division:	Division of Cardiology and Nephrology (DCN)
Application Type and Number:	NDA 213931
Product Name, Dosage Form, and Strength:	Xphozah (tenapanor) tablet, 10 mg, 20 mg, 30 mg
Applicant/Sponsor Name:	Ardelyx Inc.
TTT ID #:	2023-4878-2
DMEPA 2 Safety Evaluator:	Tayler Nalesnik, PharmD, MS
DMEPA 2 Team Leader: (acting)	Nicole Iverson, PharmD, BCPS

1 PURPOSE OF MEMORANDUM

The Applicant submitted revised container labels received on October 16, 2023 for Xphozah. We reviewed the revised container labels for Xphozah (Appendix A) to determine if they are acceptable from a medication error perspective. The revisions are in response to a recommendation that we made during a previous label and labeling review,[a] .

2 CONCLUSION

The Applicant implemented our recommendation, and we have no additional recommendations at this time.

[a] Nalesnik, Tayler. Label and Labeling Review Memo for Xphozah (NDA 213931). Silver Spring (MD): FDA, CDER, OSE, DMEPA 2 (US); 2023 Oct 04. TTT ID No.: 2023-4878-1.

APPENDIX A. IMAGES OF LABEL AND LABELING RECEIVED ON OCTOBER 16, 2023

Container labels

(b) (4)



2 Page(s) of Draft Labeling have been Withheld in Full as b4 (CCI/TS) immediately following this page

---

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

TAYLER E NALESNIK
10/17/2023 10:43:15 AM

NICOLE F IVERSON
10/17/2023 01:01:42 PM

MEMORANDUM

REVIEW OF REVISED LABEL AND LABELING
Division of Medication Error Prevention and Analysis 2 (DMEPA 2)
Office of Medication Error Prevention and Risk Management (OMEPRM)
Office of Surveillance and Epidemiology (OSE)
Center for Drug Evaluation and Research (CDER)

Date of This Memorandum:	October 4, 2023
Requesting Office or Division:	Division of Cardiology and Nephrology (DCN)
Application Type and Number:	NDA 213931
Product Name, Dosage Form, and Strength:	Xphozah (tenapanor) tablet, 10 mg, 20 mg, 30 mg
Applicant/Sponsor Name:	Ardelyx Inc.
TTT ID #:	2023-4878-1
DMEPA 2 Safety Evaluator:	Tayler Nalesnik, PharmD, MS
DMEPA 2 Team Leader: (acting)	Nicole Iverson, PharmD, BCPS

1 PURPOSE OF MEMORANDUM

The Applicant submitted revised container labels received on September 12, 2023 and September 29, 2023 for Xphozah. We reviewed the revised container labels for Xphozah (Appendix A) to determine if they are acceptable from a medication error perspective. The revisions are in response to recommendations that we made during a previous label and labeling review.[a] We note the Applicant proposed to retain the current wording for the storage statement as, "Store at 20°C to 25°C (68°F to 77°F); excursions permitted 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]". Additionally, the Applicant did not include instructions, "Keep the bottle tightly close. Store and dispense in original bottle with desiccant." in the storage statement, as this statement is redundant (b) (4) (b) (4). We find the Applicant's storage instructions acceptable.

2 CONCLUSION

We performed a risk assessment of the proposed container labels and find the revised labels are unacceptable from a medication error perspective. We acknowledge that the applicant had

[a] Nalesnik, Tayler. Label and Labeling Review for Xphozah (NDA 213931). Silver Spring (MD): FDA, CDER, OSE, DMEPA 2 (US); 2023 Aug 29. TTT ID No.: 2023-4878.

to relocate the graphic, [redacted] (b) (4) to the left of the proprietary name in order to accommodate the statement "Professional Sample Not For Sale" on principal display panel of the physician sample labels. This new placement of the graphic is consistent among all the container labels submitted. Upon reviewing the submitted container labels, the placement of the graphic in front of the letter "X" in the proprietary name is prominent. Placement of the graphic in front of the first letter in the proprietary name competes with readability of the proprietary name, which may lead to misinterpretation of the proprietary name as "tXPHOZAH". We provide a recommendation to the applicant in Section 3.

3 RECOMMENDATIONS FOR ARDELYX INC.

We recommend the following be implemented prior to approval of this NDA:

A. Container Labels and Professional Sample Labels

1. The placement of the graphic in front of the first letter "X" in the proprietary name is prominent. Placement of a graphic immediately in front of the first letter in competes with readability of the proprietary name and can lead to misinterpretation of the proprietary name as "tXPHOZAH". We recommend moving or decreasing the prominence of the graphic in front of the proprietary name to avoid misinterpretation of the proprietary name.

APPENDIX A. IMAGES OF LABEL AND LABELING RECEIVED ON SEPTEMBER 12, 202

Container labels

(b) (4)



2 Page(s) of Draft Labeling have been Withheld in Full as b4 (CCI/TS) immediately following this page

---

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

TAYLER E NALESNIK
10/04/2023 01:20:49 PM

NICOLE F IVERSON
10/04/2023 02:12:55 PM

FOOD AND DRUG ADMINISTRATION
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion

****Pre-decisional Agency Information****

Memorandum

Date: October 4, 2023

To: Austin H. Hu, M.D., Medical Officer
Division of Cardiology and Nephrology (DCN)

Sabry Soukehal, Regulatory Project Manager (DCN)

From: Charuni Shah, Regulatory Review Officer
Office of Prescription Drug Promotion (OPDP)

CC: Sapna Shah, Team Leader, OPDP

Subject: OPDP Labeling Comments for Xphozah (tenapanor) tablets, for oral use

NDA: 213931

In response to DCN's consult request dated July 22, 2023, OPDP has reviewed the proposed product labeling (PI) and Carton/Container labeling for Xphozah (tenapanor) tablets, for oral use (Xphozah) Non-responsive

PI, C/C: OPDP's comments on the proposed labeling are based on the draft version received by electronic mail from DCN on October 2, 2023, and are provided below.

A combined OPDP and Division of Medical Policy Programs (DMPP) review will be completed and comments on the proposed MG will be sent under separate cover at a later time.

Thank you for your consult. If you have any questions, please contact Charuni Shah at (240) 402-4997 or charuni.shah@fda.hhs.gov.

16 Page(s) of Draft Labeling have been Withheld in Full as b4 (CCI/TS) immediately following this page

---

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

CHARUNI P SHAH
10/04/2023 02:38:28 PM

LABEL AND LABELING REVIEW
Division of Medication Error Prevention and Analysis 2 (DMEPA 2)
Office of Medication Error Prevention and Risk Management (OMEPRM)
Office of Surveillance and Epidemiology (OSE)
Center for Drug Evaluation and Research (CDER)

*** This document contains proprietary information that cannot be released to the public***

Date of This Review:	August 29, 2023
Requesting Office or Division:	Division of Cardiology and Nephrology (DCN)
Application Type and Number:	NDA 213931
Product Name, Dosage Form, and Strength:	Xphozah (tenapanor) tablet, 10 mg, 20 mg, 30 mg
Product Type:	Single Ingredient Product
Rx or OTC:	Prescription (Rx)
Applicant/Sponsor Name:	Ardelyx Inc.
FDA Received Date:	June 29, 2020, April 17, 2023 and July 18, 2023
TTT ID #:	2023-4878
DMEPA 2 Safety Evaluator:	Tayler Nalesnik, PharmD
DMEPA 2 Team Leader:	Hina Mehta, PharmD

1 REASON FOR REVIEW

Ardelyx, Inc. submitted a response to complete response Xphozah (tenapanor) tablet on April 17, 2023. We reviewed the proposed Xphozah prescribing information (PI), container labels, and carton labeling for areas of vulnerability that may lead to medication errors.

1.1 REGULATORY HISTORY

Ardelyx, Inc submitted a 505(b)(1) for NDA 213931 Xphozah tablets on June 29, 2020, with the proposed indication of serum phosphorus control in adult patients with chronic kidney disease (CKD) on dialysis. On July 28, 2021, the application received a Complete Response for clinical issues.

2 MATERIALS REVIEWED

We considered the materials listed in Table 1 for this review. The Appendices provide the methods and results for each material reviewed.

Table 1. Materials Considered for this Review	
Material Reviewed	Appendix Section (for Methods and Results)
Product Information/Prescribing Information	A
Previous DMEPA Reviews	B
ISMP Newsletters*	C – N/A
FDA Adverse Event Reporting System (FAERS)*	D – N/A
Other	E – N/A
Labels and Labeling	F

N/A=not applicable for this review
*We do not typically search FAERS or ISMP Newsletters for our label and labeling reviews unless we are aware of medication errors through our routine postmarket safety surveillance

3 OVERALL ASSESSMENT OF THE MATERIALS REVIEWED

We note Ardelyx, Inc. did not resubmit the container labels with the resubmission and only referred to the container labels from the original application. We also note the indication statement was updated and is now being proposed for adult patients on dialysis who have had an inadequate response or intolerance to a phosphate binder therapy.

We reviewed the proposed container labels, PI, and patient information to determine whether there are any vulnerabilities that may lead to medication errors. We identified areas of the proposed PI and container labels that could be revised to improve clarity and readability of important information. For the Division, we note there needs to be clarity on the administration time and dosage adjustment on dialysis days. For the Applicant, we note lack of readability of the established name, the format of the expiration date is not defined, prominence of Rx only statement, and terminology inconsistent with the PI. These factors may confuse the user and

inadvertently lead to medication errors. We provide recommendations for the Division in Section 4.1 and the Applicant in Section 4.2 to address these deficiencies.

4 CONCLUSION & RECOMMENDATIONS

We identified areas in the proposed container label and PI that can be improved to increase readability and prominence of important information and promote the safe use of the product. We provide recommendations in Section 4.1 for the Division and Section 4.2 for Ardelyx Inc. to address our concerns.

4.1 RECOMMENDATIONS FOR DIVISION OF CARDIOLOGY AND NEPHROLOGY (DCN)

A. Highlights of Prescribing Information
    1. There are two statements in regards to administration timing: "Recommended dosage: 30 mg orally twice daily before the morning and evening meals." and "Take just prior to the first and last meals of the day." We recommend revising and combining the statements for clarity. Revise to "Recommended dosage: 30 mg orally twice daily administered prior to the first meal and prior to the last meal of the day (2.1)".

B. Prescribing Information
    1. Dosage and Administration Section
        a. As currently presented, Section 17, Patient Counseling Information, includes information on administration of the drug prior to hemodialysis. However, this information is not included under Section 2, Dosage and Administration. We recommend also providing this information under Section 2 to avoid confusion and minimize risk of dosage administration errors.
        b. As currently presented, the statement (b) (4) is unclear. No further specific dosing information is given on when and how to dose adjust according to serum phosphorous levels, which can lead to incorrect and inappropriate dose adjustments and subsequently medication errors. We recommend adding a dosage adjustment section under Section 2.2 and include specific and clear instructions on how dose adjustments should be done.
    2. Dosage Forms and Strengths
        a. We recommend revising the statement (b) (4) for simplicity to "Xphozah tablets available as:…".

4.2 RECOMMENDATIONS FOR ARDELYX INC.

We recommend the following be implemented prior to approval of this NDA:

A. Container Labels and Professional Sample Labels

1. As currently presented, the light green font color used for the established name and dosage form is hard to read. We recommend revising the font color of the established name to increase readability and prevent confusion. Please refer to 21 CFR 201.10(g)(2), which states that the established name shall be printed in letters that are at least half as large as the letters comprising the proprietary name or designation with which it is joined, and the established name shall have a prominence commensurate with the prominence with which such proprietary name or designation appears, taking into account all pertinent factors, including typography, layout, contrast, and other printing features.
2. We recommend revising the (b) (4) statements on the principal display panel for clarity and to remove the (b) (4) statement to ensure this important information is not missed. Revise to "Attention: Dispense and store XPHOZAH in original container with the desiccant to protect from moisture.".
3. As currently presented, the location of the lot number and expiration date is missing. Please confirm the location of this important information. In addition, to minimize confusion and reduce the risk for deteriorated drug medication errors, we recommend identifying the expiration date format you intend to use for the expiration date. FDA recommends that the human-readable expiration date on the drug package label include a year, month, and non-zero day. FDA recommends that the expiration date appear in YYYY-MM-DD format if only numerical characters are used or in YYYY-MMM-DD if alphabetical characters are used to represent the month. If there are space limitations on the drug package, the human-readable text may include only a year and month, to be expressed as: YYYY-MM if only numerical characters are used or YYYY-MMM if alphabetical characters are used to represent the month. FDA recommends that a hyphen or forward slash to separate the portions of the expiration date. Carton Labeling
4. According to the Prescribing Information, the dose can vary depending on the patient and serum phosphate levels. We recommend revising the dosing and administration statement to read: "Recommended Dosage: See Prescribing Information."
5. The "Rx only" statement should not compete in size and prominence with critical information on the principal display panel, and therefore we recommend this statement be de-bolded.
6. We recommend revising the storage instructions on the side panel of the container labels to the following: "Store at 68°F to 77°F (20°C to 25°C); excursions permitted between 15°C to 30°C (59°F to 86°F) [See USP controlled room temperature]. Keep the bottle tightly closed. Store and dispense in original bottle with desiccant.".

B. Professional Sample Container Labels

1. As currently presented, the statement "PROFESSIONAL SAMPLE – NOT FOR SALE" is [redacted] (b) (4). Not displaying this statement on the Principal Display Panel may lead to dispensing errors. We recommend moving this statement to the principal display panel in accordance with 21 CFR 203.38(c).

APPENDICES: METHODS & RESULTS FOR EACH MATERIALS REVIEWED

APPENDIX A. PRODUCT INFORMATION/PRESCRIBING INFORMATION

Table 2 presents relevant product information for Xphozah received on April 17, 2023 from Ardelyx Inc..

Table 2. Relevant Product Information for Xphozah	
Initial Approval Date	N/A
Active Ingredient	tenapanor
Indication	The control of serum phosphorus in adult patients with chronic kidney disease on dialysis who have had an inadequate response or intolerance to a phosphate binder therapy.
Route of Administration	oral
Dosage Form	tablet
Strength	10 mg, 20 mg, 30 mg
Dose and Frequency	Recommended dosage is 30 mg orally twice daily, immediately before first and last meals.
How Supplied	Supplied as 10 mg, 20 mg, or 30 mg oval, biconvex, film-coated tablets supplied in white, opaque, high-density polyethylene bottles containing 60 or 14 tablets with a silica gel canister (as the desiccant).
Storage	Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Keep bottle tightly closed to protect from moisture. Store and dispense in original bottle with the desiccant.

APPENDIX B. PREVIOUS DMEPA REVIEWS

On July 5, 2023, we searched for previous DMEPA reviews relevant to this current review using the terms, 'Xphozah' and NDA 213931. Our search identified one previous review[a], and we considered our previous recommendations to see if they are applicable for this current review.

[a] Aidoo, Mariette. Label and Labeling Review for Xphozah (NDA 213931). Silver Spring (MD): FDA, CDER, OSE, DMEPA (US); 2021 01 15. OSE RCM No.: 2020-1347.

APPENDIX F. LABELS AND LABELING

F.1 List of Labels and Labeling Reviewed

Using the principles of human factors and Failure Mode and Effects Analysis,[b] along with postmarket medication error data, we reviewed the following Xphozah labels and labeling submitted by Ardelyx Inc..

- Container label received on April 23, 2021.
- Carton labeling received on April 23, 2021.
- Professional Sample Carton Labeling received on April 23, 2021.
- Prescribing Information (Image not shown) received on April 17, 2023, available from \\CDSESUB1\EVSPROD\nda213931\0035\m1\us\114-labeling\draft\annotated\annotated-draft-labeling-text.pdf

F.2 Label and Labeling Images

(b) (4)

[b] Institute for Healthcare Improvement (IHI). Failure Modes and Effects Analysis. Boston. IHI:2004.

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

TAYLER E NALESNIK
08/29/2023 12:51:05 PM

HINA S MEHTA
08/29/2023 08:58:47 PM

LABEL AND LABELING REVIEW
Division of Medication Error Prevention and Analysis (DMEPA)
Office of Medication Error Prevention and Risk Management (OMEPRM)
Office of Surveillance and Epidemiology (OSE)
Center for Drug Evaluation and Research (CDER)

*** This document contains proprietary information that cannot be released to the public***

Date of This Review:	January 15, 2021
Requesting Office or Division:	Division of Cardiology and Nephrology (DCN)
Application Type and Number:	NDA 213931
Product Name, Dosage Form, and Strength:	Xphozah (tenapanor hydrochloride) tablets, 10 mg, 20 mg and 30 mg
Product Type:	Single Ingredient Product
Rx or OTC:	Prescription (Rx)
Applicant/Sponsor Name:	Ardelyx, Inc. (Ardelyx)
FDA Received Date:	June 29, 2020 and October 6, 2020
OSE RCM #:	2020-1347
DMEPA Safety Evaluator:	Mariette Aidoo, PharmD, MPH
DMEPA Team Leader:	Hina Mehta, PharmD

1 REASON FOR REVIEW

As a part of the NDA review process for NDA 213931 Xphozah (tenapanor hydrochloride) tablets, this review evaluates the proposed container labels, Prescribing Information (PI), and Patient Information for areas of vulnerability that could lead to medication errors.

2 MATERIALS REVIEWED

We considered the materials listed in Table 1 for this review. The Appendices provide the methods and results for each material reviewed.

Table 1. Materials Considered for this Review	
Material Reviewed	Appendix Section (for Methods and Results)
Product Information/Prescribing Information	A
Previous DMEPA Reviews	B
Human Factors Study	C – N/A
ISMP Newsletters*	D – N/A
FDA Adverse Event Reporting System (FAERS)*	E – N/A
Other	F – N/A
Labels and Labeling	G

N/A=not applicable for this review
*We do not typically search FAERS or ISMP Newsletters for our label and labeling reviews unless we are aware of medication errors through our routine postmarket safety surveillance

3 OVERALL ASSESSMENT OF THE MATERIALS REVIEWED

Ardelyx, Inc submitted a 505(b)(1) NDA 213931 Xphozah tablets on June 29, 2020, with the proposed indication of serum phosphorus control in adult patients with chronic kidney disease (CKD) on dialysis. DMEPA evaluated the proposed container labels, PI and patient information to determine whether there are any vulnerabilities that may lead to medication errors.

The proposed labels and labeling provide instructions to store and dispense Xphozah (tenapanor) tablets in the original manufacturer container versus simply retaining original packaging until dispensing. We considered that it may be necessary for pharmacies to dispense a quantity less than a full bottle (e.g., cash payers, vacation supply, or an emergency supply until patients can see the doctor for a new prescription). Furthermore, hospital pharmacies may repackage Xphozah (tenapanor) tablets into unit-dose blister packs because drugs are routinely dispensed in unit-doses in the usual hospital setting. We note, Ardelyx proposes the provision of a 14-tablet count bottle as well as a 60-tablet count bottle. We emailed the Office of Pharmaceutical Quality (OPQ) to determine if Xphozah can be stored in another bottle for any given period of time. OPQ stated "the drug product is co-packaged with desiccant (b) (4) to

absorb moisture. Without the desiccant (b) (4), the tablets will quickly absorb water, leading to API decomposition and possible microbial contamination. How quickly this would happen is unclear, as this would depend to a large extent on local levels of humidity. Based on the quality information, drug product quality would likely begin to degrade in a matter of days if removed from the packaging.". However, it may also be useful to consider asking the Applicant to supply Xphozah (tenapanor) in unit-dose blister packs to ensure the safe and effective use of the product especially for hospital use. We defer to the review team to make that determination..

Our review of the proposed container labels, PI and patient information for Xphozah (tenapanor) identified areas where the label and labeling may be improved to promote the safe use of the product.

4 CONCLUSION & RECOMMENDATIONS

We conclude that the proposed PI, patient information, container labels for Xphozah (tenapanor) may be improved to promote the safe use of the product as described in Sections 4.1 and 4.2.

4.1 RECOMMENDATIONS FOR DIVISION OF CARDIOLOGY AND NEPHROLOGY (DCN)

A. Highlights of Prescribing Information

1. Dosage and Administration

   a. We recommend revising the first statement on dosing for clarity. Revise to "Recommended dosage: 30 mg orally twice daily before the morning and evening meals (2.1).".

   b. We recommend adding a statement regarding dosage adjustment as this is important information. We recommend adding "Manage serum phosphorus levels and intolerability with dosage adjustments (2.2).".

2. Dosage Form and Strengths

   a. We recommend adding the unit after each numerical value to prevent confusion. Revise "10, 20, 30 mg" to "10 mg, 20 mg, 30 mg".

B. Prescribing Information

1. Dosage and Administration

   a. We recommend revising the section (b) (4) (b) (4)

   b. For clarity, we recommend revising the dosage statement to read "Recommended dosage is 30 mg orally twice daily before the morning and evening meals."

c. As currently presented the statement [redacted] (b) (4) is not clear. [redacted] (b) (4) Obtaining clarity on this statement is important.

d. The third bullet recommends dose adjustment of XPHOZAH to maintain serum phosphorus at target levels or to manage gastrointestinal tolerability. However, instructions on when and how to adjust levels are not provided. We recommend adding a dosage adjustment as Section 2.2 and include specific instructions on how adjustments should be done.

2. Dosage Forms and Strengths

   a. Revise the statement to reduce redundancy. Revise to read "XPHOZAH tablets available as:……".

3. How Supplied/Storage and Handling Section

   a. We recommend tabulating the bulleted information regarding strength and NDC labeled bottles per count into the descriptive table that denotes how Xphozah is supplied.

   b. Revise the storage statement to aid users in understanding why the product must be stored in the original container. Revise to:

      "Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].

      Keep bottle tightly closed to protect from moisture.

      Store and dispense in original bottle with the desiccant.".

4. Patient Counseling Information

   a. Revise the second bullet under Administration and Handling Instructions on dosage on hemodialysis days per revision to Section 2. As currently presented the statement is not clear.

4.2 RECOMMENDATIONS FOR ARDELYX, INC. (ARDELYX)

We recommend the following be implemented prior to approval of this NDA:

A. Container and Professional Sample Labels

   1. As currently presented the light green font color used for the established name and dosage form is hard to read. We recommend revising the font color of the established name to increase readability and prevent confusion. Revise the

established name taking into account all pertinent factors, including typography, layout, contrast, and other printing features in accordance with 21 CFR 201.10(g)(2).

2. We recommend revising the (b) (4) statements on the principal display panel for clarity and to remove the (b) (4) statement to ensure this important information is not missed. Revise to "Attention: Dispense and store XPHOZAH in original container with the desiccant to protect from moisture.".
3. As currently prevented the location of the lot and expiration date is missing. Please confirm the location of this important information. In addition, the format of the expiration date is not defined. To minimize confusion and reduce the risk for deteriorated drug medication errors, identify the format you intend to use for the expiration date. We recommend that the human-readable expiration date on the drug package label include a year, month, and non-zero day. We recommend that the expiration date appear in YYYY-MM-DD format if only numerical characters are used or in YYYY-MMM-DD if alphabetical characters are used to represent the month. If there are space limitations on the drug package, the human-readable text may include only a year and month, to be expressed as: YYYY-MM if only numerical characters are used or YYYY-MMM if alphabetical characters are used to represent the month. We recommend that a hyphen or a space be used to separate the portions of the expiration date.[5]
4. As the dose can vary especially for patients on dialysis days we recommend revising the dosing and administration statement to read: "Recommended Dosage: See Prescribing Information."
5. Decrease the prominence of the statement "Rx Only" by de-bolding the font on the principle display panel as currently presented it is more prominent than other important information.
6. Revise the storage instructions on the side panel of the container labels to the following: "Store at 68°F to 77°F (20°C to 25°C); excursions permitted between 15°C to 30°C (59°F to 86°F) [See USP controlled room temperature]. Keep the bottle tightly closed. Store and dispense in original bottle with desiccant."
7. For the professional samples, we recommend moving the statement "PROFESSIONAL SAMPLE – NOT FOR SALE" to the principal display panel as

[5] Guidance for Industry: Product Identifiers Under the Drug Supply Chain Security Act Questions and Answers. 2018. Available from https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM621044.pdf

currently presented it is [redacted] (b) (4) not prominent. APPENDICES: METHODS & RESULTS FOR EACH MATERIALS REVIEWED

APPENDIX A. PRODUCT INFORMATION/PRESCRIBING INFORMATION

Table 2 presents relevant product information for Xphozah received on June 29, 2020 and October 6, 2020 from Ardelyx, Inc. (Ardelyx).

Table 2. Relevant Product Information for Xphozah	
Initial Approval Date	n/a
Active Ingredient	tenapanor hydrochloride
Indication	Control of serum phosphorus levels in adult patients with Chronic Kidney Disease (CKD) on dialysis
Route of Administration	Oral
Dosage Form	tablets
Strength	10 mg, 20 mg and 30 mg
Dose and Frequency	Initiate at: 30 mg orally twice daily *Max Dose: 60 mg per day* *NB: Take tenapanor immediately prior to breakfast or the first meal of the day and just prior to dinner.*
How Supplied	<u>Commercial</u> 10 mg, 20 mg, 30 mg 60 count per HDPE bottle 14 count per HDPE bottle <u>Physician Samples</u> 10 mg, 20 mg, 30 mg 14 count per HDPE bottle
Storage	Store at room temperature, between 68°F and 77°F (20°C and 25°C); excursions permitted between 15°C and 30°C (59°F to 86°F) [See USP controlled room temperature]. [redacted] (b) (4)
Container Closure	- Round white HDPE bottle White, - Contains tablets with a silica gel canister (as the desiccant) and screw-top polypropylene child-resistant cap lined with an induction-activated aluminum foil liner.

APPENDIX B. PREVIOUS DMEPA REVIEWS

On October 16, 2020, we searched for previous DMEPA reviews relevant to this current review using the terms, (b) (4), 'xphozah', IND 120566 and NDA 213931. Our search identified no previous reviews.

APPENDIX G. LABELS AND LABELING

G.1 List of Labels and Labeling Reviewed

Using the principles of human factors and Failure Mode and Effects Analysis,[a] along with postmarket medication error data, we reviewed the following Xphozah labels and labeling submitted by Ardelyx, Inc. (Ardelyx).

- Container label received on June 29, 2020
- Carton labeling received on June 29, 2020
- Professional Sample Bottles received on June 29, 2020
- Prescribing Information (Image not shown) received on June 29, 2020 and October 6, 2020 available from \\CDSESUB1\evsprod\nda213931\0008\m1\us\draft-labeling-text.doc

G.2 Label and Labeling Images

(b) (4)

[a] Institute for Healthcare Improvement (IHI). Failure Modes and Effects Analysis. Boston. IHI:2004.

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

MARIETTE A AIDOO
01/20/2021 03:30:52 PM

HINA S MEHTA
01/20/2021 04:04:57 PM